Wednesday, April 8, 2026 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

In the rapidly evolving landscape of moderate-to-severe atopic dermatitis (AD), managed care professionals are navigating innovative therapies that promise enhanced efficacy, longer-lasting relief, and streamlined dosing— yet challenges like therapy limitations, social determinants of health (SDOH), adherence hurdles, and adverse events continue to disrupt patient outcomes and drive up costs.

Drawing from a dynamic November 2025 virtual roundtable featuring a key opinion leader (KOL), six influential payer panelists, and authentic patient perspectives, this webinar distills critical highlights to empower US managed care pharmacists. We’ll dive deep into real-world barriers beyond the clinic, exploring how SDOH, coverage gaps, care fragmentation, and side effect management influence treatment success. Gain evidence-based strategies and payer-centric tools to bridge these gaps, foster equitable access, and deliver measurable value in a competitive market.

Attendees will emerge equipped with forward-thinking insights to transform AD care delivery, from rethinking prior authorizations to leveraging real-world data for smarter decision-making.

Key Discussion Points: 

• Uncovering hidden barriers: Tackling SDOH, delayed diagnoses, and specialist access shortages to promote equitable care.
• Weighing innovations head-on: Assessing emerging agents' strengths against therapy limitations, side effects, and real-world performance of established options.
• Boosting adherence in practice: Examining how costs, coverage policies, and patient support programs directly impact long-term compliance and outcomes.
• Actionable payer strategies: Deploying proven practices to streamline the AD patient journey, minimize disruptions, and maximize value for all stakeholders.